Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Karyopharm Therapeutics (KPTI) over the last 12 years, with Q4 2025 value amounting to $8.7 million.

  • Karyopharm Therapeutics' Non-cash Items changed N/A to $8.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.7 million, marking a year-over-year change of. This contributed to the annual value of $8.7 million for FY2025, which is N/A changed from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Non-cash Items of $8.7 million as of Q4 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Non-cash Items peaked at $8.7 million during Q4 2025, and registered a low of $6000.0 during Q4 2022.
  • For the 3-year period, Karyopharm Therapeutics' Non-cash Items averaged around $3.7 million, with its median value being $2.3 million (2021).
  • Per our database at Business Quant, Karyopharm Therapeutics' Non-cash Items crashed by 9480.1% in 2021 and then tumbled by 9973.79% in 2022.
  • Karyopharm Therapeutics' Non-cash Items (Quarter) stood at $2.3 million in 2021, then plummeted by 99.74% to $6000.0 in 2022, then soared by 144900.0% to $8.7 million in 2025.
  • Its last three reported values are $8.7 million in Q4 2025, $6000.0 for Q4 2022, and $2.3 million during Q4 2021.